BB1 Shares BlinkLab Limited
ACCUMULATE ASX · ASXDigital diagnostics development and anticipated milestones offer high-risk, high-upside optionality.
Future value: $2.24 (+267.21%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Expected clinical and regulatory milestone catalysts
- ▾Below 50-day MA (-12.73%)
- ▾Near 52-week low (9.2% of range)
- ▸~267% upside to price target
Is BB1 a buy right now?
Trend: BB1 is trading below the 50-day average (-10.14%), RSI 44 — neutral momentum, with a 3-month return of -11.43%.
Valuation & quality: BlinkLab Limited trades on forward P/E -12.7, price-to-book 4.84; fundamentals show net margin 0.0%, return on equity -50.7%, revenue growth 386.5% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$2.24 (+267.2% vs the last close; range A$1.76 – A$3.06), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Digital diagnostics development and anticipated milestones offer high-risk, high-upside optionality.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -13.00% | -17.50% | +0.00% | -6.10% | +9.70% | +11.80% | -9.20% | -10.10% |
Fundamentals
Analyst price target
Technical signals
About BlinkLab Limited
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.